The kinetics of clonal dominance in myeloproliferative disorders
نویسندگان
چکیده
منابع مشابه
The kinetics of clonal dominance in myeloproliferative disorders.
To study clonal evolution in myeloproliferative disorders, we used stochastic models of hematopoiesis for mouse and cat, species for which the in vivo kinetics of hematopoietic stem cells (HSCs) have been experimentally defined. We determined the consequence if 1 HSC became able to survive without the support of a microenvironmental niche while the rest of its behavior did not change. Neoplasti...
متن کاملOncogenes in myeloproliferative disorders.
Myeloproliferative disorders (MPDs) constitute a group of hematopoietic malignancies that feature enhanced proliferation and survival of one or more myeloid lineage cells. William Dameshek is credited for introducing the term "MPDs" in 1951 when he used it to group chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) under one cl...
متن کاملthe effect of the record infancy in crimilly acts of guilties (in karaj city)
چکیده یکی از مهمترین دغدغه های بزرگ جوامع بشری، از دیر باز تا کنون که ذهن پژوهشگران و متخصصان بهداشت روانی و اجتماعی و دولتها رابه خود مشغول داشته، مسأله ی بزهکاری می باشد. شناخت کامل پدیده ی بزهکاری و بزهکار، علل وعوامل سقوط یک انسان، چگونگی درمان وی و درنهایت پیشگیری ازبزهکاری ودریک کلام سالم سازی یک جامعه، رسالت عظیم، انسانی ومقدسی می باشد که با بررسی شخصیت مجرم یعنی[ انسانی که تحت شرای...
15 صفحه اولMyeloproliferative disorders and its associated mutations
Myeloproliferative Neoplasm (MPN) are a clonal disorder in hematopoietic stem cells (HSC). MPN is categorized to 8 subclasses, including chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocytopenia (ET), primary myelofibrosis (PMF), systematic mastositosis (SM), chronic eosinophilic leukemia (CEL), chronic neutrophilic leukemia (CNL), and unclassified myelofibrosis disorde...
متن کامل32P in the treatment of myeloproliferative disorders
UNLABELLED (32)P has been available for the treatment of myeloproliferative neoplasms (MPNs) for over seventy years. It was first used in 1938 by John H Lawrence in the treatment of polycythaemia and chronic leukaemias. With the introduction of agents such as hydroxycarbamide, interferon and anagrelide the role of (32)P has been diminished. Today, Polycythaemia Rubra Vera (PRV) and Essential Th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2005
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2005-03-1240